Integral Health Asset Management LLC Buys 10,000 Shares of Penumbra, Inc. $PEN

Integral Health Asset Management LLC increased its stake in shares of Penumbra, Inc. (NYSE:PEN) by 25.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 50,000 shares of the company’s stock after acquiring an additional 10,000 shares during the quarter. Integral Health Asset Management LLC’s holdings in Penumbra were worth $12,666,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of PEN. Vanguard Group Inc. increased its stake in shares of Penumbra by 5.0% during the second quarter. Vanguard Group Inc. now owns 3,860,655 shares of the company’s stock worth $990,760,000 after purchasing an additional 185,306 shares during the period. Geode Capital Management LLC boosted its stake in Penumbra by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 706,404 shares of the company’s stock valued at $181,314,000 after purchasing an additional 17,772 shares during the period. Invesco Ltd. grew its holdings in Penumbra by 1,139.3% in the 2nd quarter. Invesco Ltd. now owns 633,485 shares of the company’s stock valued at $162,571,000 after buying an additional 582,369 shares in the last quarter. Norges Bank acquired a new position in shares of Penumbra in the second quarter valued at about $114,014,000. Finally, Thrivent Financial for Lutherans increased its position in Penumbra by 13.7% during the third quarter. Thrivent Financial for Lutherans now owns 367,062 shares of the company’s stock worth $92,984,000 after acquiring an additional 44,185 shares during the period. Institutional investors and hedge funds own 88.88% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on PEN. Truist Financial downgraded shares of Penumbra from a “buy” rating to a “hold” rating and boosted their price objective for the company from $370.00 to $374.00 in a report on Friday, January 16th. Wall Street Zen downgraded Penumbra from a “buy” rating to a “hold” rating in a research note on Saturday, January 17th. Citigroup downgraded shares of Penumbra from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $350.00 to $374.00 in a research note on Thursday, January 15th. Bank of America raised their target price on shares of Penumbra from $320.00 to $370.00 and gave the company a “buy” rating in a report on Monday, January 5th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Penumbra in a research note on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $361.69.

Penumbra Stock Up 0.3%

Shares of NYSE:PEN opened at $336.05 on Friday. Penumbra, Inc. has a 52-week low of $221.26 and a 52-week high of $362.41. The company has a market capitalization of $13.19 billion, a PE ratio of 74.35, a price-to-earnings-growth ratio of 2.05 and a beta of 0.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.29 and a current ratio of 6.64. The company has a fifty day moving average of $340.38 and a 200-day moving average of $297.57.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of $1.12 by ($1.49). The firm had revenue of $385.39 million for the quarter, compared to analyst estimates of $367.18 million. Penumbra had a net margin of 12.66% and a return on equity of 11.41%. The company’s revenue was up 22.2% compared to the same quarter last year. During the same period last year, the business earned $0.97 EPS. On average, equities analysts predict that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insider Activity at Penumbra

In other news, CFO Maggie Yuen sold 2,432 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $342.30, for a total value of $832,473.60. Following the completion of the sale, the chief financial officer owned 18,353 shares of the company’s stock, valued at approximately $6,282,231.90. This represents a 11.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Thomas Wilder sold 186 shares of Penumbra stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $310.72, for a total value of $57,793.92. The SEC filing for this sale provides additional information. Insiders sold a total of 2,804 shares of company stock worth $948,419 in the last quarter. 4.20% of the stock is owned by insiders.

Penumbra Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.